CAR T Cell Therapy Market Industry Trends and Global Forecasts to 2035: Rising Leukemia and Lymphoma Cases Boost CAR T Cell Therapy Market, with Positive Phase III Trials Expanding Treatment Potential
05 juin 2024 08h03 HE
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical...
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
04 juin 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
04 juin 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
31 mai 2024 08h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
29 mai 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Reports Financial Results for First Quarter 2024
28 mai 2024 16h30 HE
|
Cellectis Inc.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference...
CARGO Therapeutics to Participate in Upcoming Investor Conferences
28 mai 2024 08h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
27 mai 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
17 mai 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Monthly information on share capital and company voting rights
16 mai 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...